8,478 reports of this reaction
2.5% of all CLOPIDOGREL reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for CLOPIDOGREL, manufactured by Sanofi-Aventis U.S. LLC. There are 8,478 FDA adverse event reports linking CLOPIDOGREL to FATIGUE. This represents approximately 2.5% of all 332,980 adverse event reports for this drug.
Patients taking CLOPIDOGREL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for CLOPIDOGREL, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for CLOPIDOGREL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 8,478 FDA reports for CLOPIDOGREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.5% of all adverse event reports for CLOPIDOGREL, making it one of the most commonly reported side effect.
If you experience fatigue while taking CLOPIDOGREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.